AbbVie gains rights to Lupin's MALT1 inhibitors for development in haematological cancers

AbbVie licensed exclusive global rights to Lupin's MALT1 inhibitor programme, which the US drugmaker plans to develop across a range of haematological cancers, the companies announced Monday. Under the deal, AbbVie will make an upfront payment of $30 million to Lupin, with the latter eligible to receive milestones of up to $947 million, as well as double-digit royalties on sales.

Tom Hudson, vice president of discovery at AbbVie, noted that "Lupin's MALT1 programme is exploring a new and innovative approach in difficult-to-treat cancers," while Raj Kamboj, president of Lupin's novel drug discovery and development, indicated "this is a first-in-class drug discovery programme delivered exclusively by Lupin right from concept generation through the various stages of drug discovery and development."

While AbbVie will have rights to develop and market drugs targeting MALT-1, a protein involved in T-cell and B-cell lymphocyte activation, Lupin will retain commercial rights to the programme in India.

To read more Top Story articles, click here.